Literature DB >> 25041120

Belatacept: is there BENEFIT for liver transplantation too?

S J Knechtle, A B Adams.   

Abstract

The results of the multicenter belatacept liver transplant trial disappoint with respect to safety and efficacy, and new approaches will be required before this agent plays a role in liver transplant immunosuppression. See article by Klintmalm et al on page 1817.

Mesh：

Substances：

Year:  2014        PMID： 25041120     DOI： 10.1111/ajt.12806

Source DB:  PubMed          Journal:  Am J Transplant        ISSN： 1600-6135            Impact factor:   8.086


  4 in total

1.  A Systematic Review of the Literature on Chronic Kidney Disease Following Liver Transplantation.

Authors:  Hitomi Miyata; Yoshiaki Morita; Anil Kumar
Journal:  Ann Transplant       Date:  2022-05-24       Impact factor: 1.479

Review 2.  Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants.

Authors:  Dhiren Kumar; Spencer LeCorchick; Gaurav Gupta
Journal:  Front Med (Lausanne)       Date:  2017-05-19

Review 3.  Costimulation Blockade in Kidney Transplant Recipients.

Authors:  Marieke van der Zwan; Dennis A Hesselink; Martijn W F van den Hoogen; Carla C Baan
Journal:  Drugs       Date:  2020-01       Impact factor: 9.546

4.  Belatacept Conversion in Kidney After Liver Transplantation.

Authors:  Octav Cristea; Geeta Karadkhele; William H Kitchens; Payaswini Vasanth; Christian P Larsen; Idelberto R Badell
Journal:  Transplant Direct       Date:  2021-10-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.